Abstract: Ojeok-san is a frequently used herbal medication for the management of osteoarthritic pain. We evaluated the effect of Ojeok-san on the pharmacokinetics of celecoxib at steady-state in healthy individuals. An open-label, fixed-sequence, two-period, two-treatment cross-over study was conducted. In period I, the individuals received celecoxib capsule 200 mg once daily for 4 days. In period II, only Ojeok-san (14.47 g/pack, three times daily) was administered for 4 days, followed by co-administration with celecoxib for 4 days. On the fourth (final) day of administration, Ojeok-san was administered as a single dose. The blood samples for pharmacokinetic evaluation were collected for up to 48 hr after the administration of celecoxib in each study period. Of the 22 enrolled individuals, 20 individuals completed the study. In the presence of Ojeok-san, the systemic exposure of celecoxib was decreased. The geometric mean ratios ([celecoxib + Ojeok-san]/celecoxib) and the 90% confidence intervals for the maximum plasma concentration (C max ) and the area under the plasma concentration-time curve during dosing interval (AUC s ) of celecoxib at steady-state were 0.725 (0.620-0.848) and 0.885 (0.814-0.962), respectively. The changes in the mean of the C max and AUC s of celecoxib were greater in intermediate metabolizers of cytochrome 2C9 (CYP2C9) than in normal metabolizers. Our results suggested that the C max and AUC s of celecoxib were reduced by Ojeok-san co-administration. This finding may be beneficial to determine the required adjustment of celecoxib dosage when co-administered with Ojeok-san.
The use of herbal medicinal products and supplements is continuously increasing globally [1] ; similarly, reports on the concurrent use of herbal supplements with prescription medications are increasing [2] . A survey conducted in the United States showed that approximately 16% of prescription medication users also reported the consumption of herbal supplements [3] . As the global use of herbal medicinal products continues to expand, public health issues and safety concerns surrounding the use of herbal medicines have received increasing recognition [4] . Specifically, patients with musculoskeletal problems characterized by chronic pain and a variable disease course are more likely to use herbal treatments [5] .
From a safety perspective, the potential interaction between medications, including conventional drugs and herbs, is one of the main obstacles to the use of herbal medicines [6] . As herbal medicines are mixtures of more than one active ingredient, the probability of interactions with other co-medications is increased [7] . Therefore, the evaluation of potential interactions between herbal remedies and conventional drugs may help to determine the required dosage adjustment.
Ojeok-san, which consists of 17 herbal medicines, is used for various indications, including the treatment of illnesses associated with fatigue, pain and fever, owing to its analgesic, anti-inflammatory and antipyretic effects [8] [9] [10] . Among the 56 traditional herbal formulae which have been supplied by the National Health Insurance Corporation in Korea, Ojeok-san has been reported as the most frequently used herbal medication; it is also the main herbal medicine preparation provided in Korean medical clinics [11] . Several components of Ojeok-san have been demonstrated to affect the activities of cytochrome P450 (CYP450) or UDP-glucuronosyltransferase (UGT), which are responsible for phase I and phase II transformation reactions, respectively [12] [13] [14] . Specifically, some components of Ojeok-san, including Zingiberis Rhizoma and Cinnamomi Cortex, have been reported to exert inhibitory activities against CYP2C9 in previous in vitro studies [15, 16] . Hence, the pharmacokinetic (PK) characteristics of the drugs metabolized by this enzyme can be altered by concomitant administration with Ojeok-san. In particular, analgesics that are likely to be co-administered with Ojeok-san may require a dosage adjustment to compensate for the PK interactions.
Among conventional drugs, celecoxib is a frequently used medication for the management of osteoarthritic pain. Although non-steroidal anti-inflammatory drugs (NSAIDs) have been mainly used for the treatment of osteoarthritic pain, the long-term use of NSAIDs is likely to result in gastrointestinal complications [17, 18] . Therefore, the cyclooxygenase-2 selective inhibitor celecoxib is representative of the new generation of NSAIDs, which provide a similar level of pain relief to non-selective NSAIDs, but with a reduced occurrence of gastrointestinal adverse events [17] .
Consequently, Ojeok-san and celecoxib, which are both frequently used for the treatment of patients with osteoarthritis, have potential to be co-administered. Thus, an investigation of the PK interaction between these two drugs may be beneficial for the provision of a rationale for dosage adjustment to achieve treatment effects with reduced adverse events in the case of co-administration.
In this study, we aimed to evaluate the effects of Ojeok-san on the PK characteristics of steady-state celecoxib in healthy individuals. Furthermore, the safety and tolerability profiles after the concomitant administration of Ojeok-san and celecoxib were also investigated.
Materials and Methods
Study population. Healthy Korean male individuals, aged 20-45 years, with a body mass index in the range of 18.0-27.0 kg/m 2 , and a total bodyweight between 50 and 90 kg were enrolled in this study. After the receipt of a detailed explanation of the study, the participants provided written informed consent and were then screened for eligibility. The screening assessments included medical history, 12-lead electrocardiography, a physical examination and clinical laboratory tests. Plasma drug concentration. For the pharmacokinetic analysis of celecoxib, the blood samples were collected prior to administration of the drug on days 1-3 and 15-17. At steady-state, on days 4 and 18, the blood samples were collected before dosing (0 hr) and at 0.5, 1, 1.5, 2, 2.33, 2.67, 3, 3.5, 4, 6, 8, 12, 24 and 48 hr after the administration of the drug in each study period. At each sampling time, a volume of 8 mL was collected in EDTA tubes and centrifuged at 18009 g for 10 min. at 4°C within 1 hr of sample collection. Three aliquots of supernatant (each 1 mL) were stored at À70°C until analysis.
The plasma concentrations of celecoxib were determined using a validated high-performance liquid chromatography (HPLC; Agilent 1100 series, Palo Alto, CA, USA) method coupled with an API 2000 triple-quadrupole mass spectrometer (Applied Biosystems/MDS SCIEX, Concord, ON, Canada) operated in negative electrospray ionization mode with multiple reaction monitoring (MRM). The chromatographic separation was performed under gradient conditions using a Luna HILIC (hydrophilic interaction liquid analytical chromatography) 200 A column (50 mm 9 2.0 mm, i.d., 3 lm; Phenomenex, Torrance, CA, USA) at 45°C. The mobile phase consisted of a mixture of 10 mM ammonium formate and 100% methanol (5:95, v/v), with a flow rate of 0.2 mL/min. For celecoxib and the internal standard, celecoxib-d4, the precursor-to-product ion pairs were massto-charge ratio (m/z) of 380.093?316.000 and 384.214?320.100, respectively. Matrix effects were evaluated at 15, 500 and 1600 ng/ mL for celecoxib and at 2500 ng/mL for the internal standard. The responses of the analytes from post-extracted plasma standard samples were compared with those of the analytes from pure standard samples at equivalent concentrations. The coefficient of variations (CVs) of the post-extracted plasma standard samples was 2.004%-6.111% for celecoxib and 6.484% for the internal standard, respectively. The CVs of the pure standard samples were 3.912%-5.958% for celecoxib and 5.377% for the internal standard, respectively. These results were within the acceptance criteria, and no significant matrix effects were observed. The lower limit of quantification (LLOQ) was 5 ng/mL, and the calibration was linear in the range from 5-2000 ng/mL. The intrabatch and interbatch CVs of celecoxib were ≤3.193% and ≤2.184%, respectively. The intrabatch and interbatch accuracies were in the ranges from 95.289%-104.133% and 99.311%-101.761%, respectively.
Pharmacokinetic analysis. The pharmacokinetic parameters were calculated by the non-compartmental method of Phoenix â WinNonlin â software version 6.4 (Certara, St. Louis, MO, USA). The observed values were used to estimate the maximum plasma concentration (C max ) and the time to maximum plasma concentration (T max ) at a steady-state.
The area under the plasma concentration-time curve (AUC) during the dosing interval (AUC s ) on days 4 and 18 was calculated using the linear-up log-down trapezoidal method. The terminal elimination rate constant (k z ) was estimated from the regression of the log-linear decrease in the plasma concentration-time profile; the terminal elimination half-life (t 1/2 ) was calculated from the natural logarithm of 2 divided by k z . The apparent clearance at steady-state (CL/F) was calculated from the dose divided by the AUC s at steady-state. The estimation of the apparent volume of distribution (V/F) was based on k z .
Genotype analysis. Among the two most common decreased-function mutations of CYP2C9, CYP2C9*2 and CYP2C9*3, only CYP2C9*3 was analysed, as CYP2C9*2 is not found in the Asian population, including Koreans [19] [20] [21] . A pyrosequencing method for the detection of single nucleotide polymorphisms (SNPs) for CYP2C9*3 (c.1075A>T; rs1057910) was used as previously reported [22] . Briefly, 60 lL of the polymerase chain reaction (PCR) product was placed in a single reaction well and immobilized by incubation with a mixture of 5 lL streptavidin beads (Streptavidin Sepharose High Performance, GE Healthcare Bio-Science AB, Uppsala, Sweden). The PCR products were conducted using the primers (forward: 5 0 -biotin-CAC GAG GTC CAG AGA TAC-3 0 ; reverse: 5 0 -CGG TGA TGG TAG AGG TTT A-3 0 ) with an initial denaturation step at 94°C for 3 min., followed by 40 cycles of denaturation at 94°C for 30 sec., annealing at 60°C for 30 sec. and extension at 72°C for 30 sec. A final termination step was performed at 72°C for 5 min. The beads were isolated, treated with 70% ethanol, denaturation solution (0.2 M NaOH) and wash buffer (10 mM Trisacetate, pH 7.6). The beads were subsequently transferred into a PSQ 96 Plate Low (Pyrosequencing AB) containing the sequencing primer (5 0 -TGG GGA GAA GGT CAA-3 0 ). After this solution was heated at 85°C for 2 min. and then cooled to room temperature, the mixture was analysed using a PSQ 96MA Pyrosequencer (Pyrosequencing AB) for sequence determination. The accuracy of pyrosequencing was validated through comparisons with the direct DNA sequencing of SNPs for randomly selected samples, and the results showed 100% concordance with the pyrosequencing results. Using this method, the SNPs for CYP2C9*3 were analysed in 250 Korean individuals, and the allele frequencies of CYP2C9*3 met the Hardy-Weinberg equilibrium [22] .
Safety and tolerability assessment. The data obtained from all the study participants who were administered the study drug at least once were included in the tolerability assessment. Any occurrence of adverse events (AEs) was noted during the entire study period. The changes from baseline with respect to physical examination, vital signs and clinical laboratory tests, including haematology, blood chemistry and urinalysis, were considered for the tolerability assessment.
Statistical analysis. The statistical analyses were computed by SAS (version 9.4; SAS Institute Inc., Cary, NC, USA). Using a mixed effect model, the analysis of variance (ANOVA) was performed to compare the 90% confidence intervals (90% CIs) of the geometric mean ratios (GMRs) of AUC s or C max at steady-state. In the mixed effect model, the treatments were considered as fixed effects and the subject was classified as a random effect. If the 90% CI was within the conventional bioequivalence range of 0.80-1.25, there was considered to be no significant PK difference between the two treatments. Values of p < .05 were considered statistically significant.
Results

Demographic characteristics.
Among the 22 healthy male volunteers who were enrolled in this study, 20 individuals completed the study: one subject withdrew consent prior to drug administration in period I and the other subject dropped out prior to the first Ojeok-san dose in period II, owing to adverse events (suspected gastroenteritis). The age, weight, height and body mass index of the enrolled individuals (N = 22) were 26.0 AE 4.1 years, 71.8 AE 9.0 kg, 174.6 AE 5.0 cm and 23.5 AE 2.2 kg/m 2 (mean AE standard deviation), respectively. Twenty-one individuals who received the study drug at least once were included in the safety and tolerability assessment, whereas the 20 individuals who completed the study were eligible for PK and genotype analysis and were arranged in the following categories: normal metabolizer (NM) (N = 18), intermediate metabolizer (IM; N = 2) and poor metabolizer (PM; N = 0).
Pharmacokinetic characteristics.
The co-administration of celecoxib and Ojeok-san decreased the mean C max and AUC s of celecoxib to 72.5% and 88.5%, respectively, compared with celecoxib administration alone (table 1, fig. 2 ). The trends of decrease in the C max and AUC s of celecoxib when co-administered with Ojeok-san were also observed in the individual comparisons of celecoxib ( fig. 3 ). Similar patterns were also observed in the individual analyses with respect to the CYP2C9 metabolizer phenotype. However, the extent of changes in the mean of C max and AUC s of celecoxib was greater in the CYP2C9 IM group than in the NM group, although the direct comparison was limited by the small number of individuals in the IM group. The presence of Ojeok-san prolonged the median T max of celecoxib from 2.3 to 2.7 hr and the mean t 1/2 of celecoxib from 7.1 to 11.3 hr (table 1, fig. 2 ). The individual plasma concentration-time profiles of celecoxib exhibited large interindividual variability, with more than one compartment elimination that occurred after the co-administration of celecoxib and Ojeok-san ( fig. S1 ).
Safety profiles and tolerability.
From the 21 participants, one (4.8%) in period I (celecoxib) and eight (38.1%) in period II (Ojeok-san + celecoxib) reported AEs. The most commonly reported AE, feeling hot (N = 2), occurred in period II. All AEs, including feeling hot, increased blood creatine phosphokinase level and dry mouth, were mild and recovered fully without sequelae. With the exception of one subject, who dropped out with suspected gastroenteritis prior to the first Ojeok-san dose in period II, no participants discontinued the study owing to AEs. Likewise, no clinically significant changes were noted in laboratory tests, vital signs or physical examinations throughout the entire study period.
Discussion
In this study, the systemic exposure of celecoxib, as shown by C max and AUC s , was decreased by Ojeok-san co- administration. However, the mean t 1/2 of celecoxib was prolonged, which can be explained by the greater increase in the mean V/F than in the mean CL/F in the presence of Ojeoksan. Overall, the elimination rate of celecoxib was decreased by the co-administration of Ojeok-san. Based on these findings, the co-administration of Ojeok-san appears to have affected the PK of celecoxib in both the absorption and the elimination phases.
In the absorption phase, the mean C max of celecoxib decreased to 72.5% in the presence of Ojeok-san compared with celecoxib alone. In the elimination phase, the mean t 1/2 of celecoxib was prolonged for approximately 4 hr in the presence of Ojeok-san. Together, these elements suggested that although the elimination rate and the systemic absorption of celecoxib were decreased in the presence of Ojeok-san, the extent of PK interactions between Ojeok-san and celecoxib was relatively larger in the absorption phase than in the elimination phase. Consequently, a greater decrease occurred in the mean C max than in the mean AUC s of celecoxib.
With regard to the PK interactions of Ojeok-san and celecoxib during the absorption phase, the limited study results have suggested the possible mechanisms that exist with regard to the effects of the Ojeok-san components on the gastrointestinal absorption of the concomitantly administered drug. For example, Zingiberis Rhizoma, a component of Ojeok-san, has been used for the treatment of gastrointestinal disorders owing to its acceleration of gastric emptying [23, 24] . In contrast, Atractylodis Rhizoma inhibits the secretion of gastric acid, which can alter the pH of the gastrointestinal tract [25] . As the PK of celecoxib can be altered by food intake or by co-administration with aluminium-or magnesium-containing antacids [26] , further studies may be helpful to elucidate the effects of the components of Ojeok-san on the PK profiles of celecoxib associated with gastric emptying time or changes in gastric pH.
Celecoxib is primarily metabolized to form hydroxycelecoxib, which is mediated via CYP2C9 enzyme, although CYP3A4 also plays a minor (<25%) role [27] [28] [29] . Hydroxycelecoxib is further oxidized to form carboxycelecoxib and then conjugated with glucuronic acid by UGT to form the 1-O-glucuronide [29, 30] . Ojeok-san has been reported to inhibit CYP450 enzymes, including CYP2C9 and UGT1A1, in human microsomes [12] , which suggested that the elimination pathway of celecoxib might be inhibited by Ojeok-san co-administration. According to a previous study, Ojeok-san exerted a competitive weak inhibition on the activity of CYP450 enzymes, including CYP2C9 and CYP3A4, with IC 50 values of 868.74 and 583.60 lg/mL, respectively [12] . Furthermore, Ojeok-san showed dose-dependent inhibition of UGT1A1 activity, although the IC 50 value was higher than 1000 lg/mL [12] . These results supported the prolonged mean t 1/2 of celecoxib when co-administered with Ojeok-san, as found in this study.
The PK profiles of celecoxib may be affected by the components of Ojeok-san that are associated with CYP2C9 enzyme activity. As each component of Ojeok-san has been reported to exert different effects on CYP2C9 enzyme activity, the effect of Ojeok-san on the celecoxib metabolism may be the sum of these Table 1 .
The pharmacokinetic parameters of celecoxib at steady-state after the co-administration of celecoxib and Ojeok-san or the administration of celecoxib alone. The data are summarized as the arithmetic mean AE standard deviation, except for T max , which is presented as the median [min-max].
T max , time to maximum plasma concentration; C max , maximum plasma concentration; AUC s , area under the concentration-time curve during dosing interval; t 1/2 , terminal half-life; CL/F, apparent clearance; V/F, apparent volume of distribution; CI, confidence interval; NM, normal metabolizer; IM, intermediate metabolizer. 1 The geometric mean ratio of celecoxib and Ojeok-san co-administration to celecoxib administration alone.
various effects. For example, Glycyrrhizae Radix caused the induction of CYP2C9, whereas Angelicae dahuricae delayed the elimination of tolbutamide, a substrate for CYP2C9, by the inhibition of hepatic metabolism in animal studies [31, 32] . In addition, three components of ginger (Zingiberis Rhizoma), 6-, 8-and 10-gingerol, potently inhibited CYP2C9 activity [15] . Moreover, a previous study showed that Cinnamomi Cortex and Paeoniae Radix, which are components of Ojeok-san, have inhibitory activities against CYP2C9 with IC 50 values of 58.7 and 330.2 lg/mL, respectively [16] . The large interindividual variation that was observed in the PK profiles of celecoxib with elimination through more than one compartment after the co-administration of celecoxib and Ojeok-san may be attributed to the combined interaction of celecoxib and the individual components of Ojeok-san. We also found that the extent of decreases in the mean C max and AUC s of celecoxib was larger in CYP2C9 IM individuals than in NM individuals. The systemic exposure of celecoxib was generally larger in IM individuals than in NM individuals when celecoxib was administered alone. However, owing to the possible inhibition of CYP2C9 activity in the presence of Ojeok-san, the other enzymes remaining would contribute to the metabolism of celecoxib. Additionally, it can be assumed that these other enzymes and transporters have similar effects on the celecoxib PK, which were independent of the CYP2C9 phenotype. Therefore, the difference between the CYP2C9 IM and NM individuals related the celecoxib exposure was thought to be reduced after Ojeok-san coadministration. Further studies with prospective genotype analysis and more individuals may be helpful for the clarification of the relationship between the CYP2C9 metabolizer phenotypes and the extent of drug interactions.
As the effective t 1/2 of celecoxib is approximately 11 hr [26], we believed that a final dose of Ojeok-san at approximately 7 a.m. on day 18 would be appropriate for the evaluation of the inhibition of Ojeok-san on celecoxib elimination and determine whether an inhibitory interaction existed between the two drugs. However, after the consideration of the interindividual variability in the PK profiles and dosage of Ojeok-san in clinical settings, we performed an additional pilot group study (N = 4) with an extended Ojeok-san dose on day 18 (at approximately 7 a.m., before the administration of celecoxib, and at approximately 2 p.m. and 8 p.m.). Through a comparison of the PK parameters from the two experiments results, further evaluation of the effect of Ojeok-san on the terminal t 1/2 of celecoxib was achieved. These additional results were in line with our findings: the mean C max and AUC s decreased, and the mean t 1/2 of celecoxib was prolonged from 9.3 to 13.0 hr, a similar increase to that seen in the current study (table S1, fig. S2 ).
Only limited studies exist with regard to the dose-response relationship of celecoxib. In a previous study of celecoxib dose between 100 and 800 mg, the inhibition of COX-2 activity produced by celecoxib was not dose-dependent [33] . An analysis of the four studies was performed in patients with arthritis did not reveal a clear dose-response relationship with regard to the drug effects, as well as to the frequency of withdrawals owing to the occurrence of AEs [34] . After consideration, and in combination with this study result, further investigation of the celecoxib exposure-response relationship may be helpful to determine the required adjustment of the dosage of celecoxib when co-administered with Ojeok-san.
In our study, multiple co-administrations of celecoxib and Ojeok-san were well tolerated in healthy male individuals. A possible association of some of the treatment-related AEs (i.e. dry mouth) has been reported with Ojeok-san or its components, including ephedra, as well as celecoxib [26, 35] . All AEs were considered mild in intensity, and the patients recovered fully before the end of study. Moreover, the systemic exposure of celecoxib was decreased by Ojeok-san co-administration. Therefore, based on these results, celecoxib and Ojeok-san can be administered together while maintaining a favourable safety and tolerability profile, although long-term evaluations in more patients are needed.
In conclusion, after the multiple co-administration of celecoxib and Ojeok-san, the PK of celecoxib was changed in both the absorption and elimination phases. The systemic exposure of celecoxib, as illustrated by C max and AUC s , was decreased after celecoxib and Ojeok-san co-administration in comparison with celecoxib alone. In contrast, the mean t 1/2 of celecoxib was prolonged when co-administered with Ojeoksan, which may be associated with the inhibitory effect of Ojeok-san and its components against CYP2C9. A greater decrease occurred in the mean C max than in the mean AUC s of celecoxib, which suggested a relatively larger extent of PK interactions between Ojeok-san and celecoxib in the absorption phase than in the elimination phase. Furthermore, the extent of the decrease in the systemic exposure of celecoxib appeared to be larger in CYP2C9 IM individuals than in NM individuals. Collectively, our results suggested that the combination therapy of celecoxib and Ojeok-san resulted in PK interaction. Further studies with more patients would be helpful to investigate the effects of factors, including disease status and demographic characteristics, on the PK interaction between celecoxib and Ojeok-san. Additionally, the investigation of the celecoxib exposure-response relationship may be beneficial for the determination of the required adjustment for the dosage of celecoxib when co-administered with Ojeok-san.
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Additional Supporting Information may be found online in the supporting information tab for this article: Figure S1 . The individual time-concentration profiles of celecoxib at steady state after (a) the administration of celecoxib alone or (b) the co-administration of celecoxib and Ojeok-san. The inset shows the linear scale and the red lines represent the CYP2C9 intermediate metabolizers (N = 2) . Figure S2 . The mean plasma concentration-time profiles of celecoxib at steady state after the administration of celecoxib alone or the co-administration of celecoxib and Ojeok-san in the pilot study. The error bars denote the standard deviation and the insets show the linear scale. Table S1 . The pharmacokinetics parameters of celecoxib at steady state after the co-administration of celecoxib and Ojeok-san or the administration of celecoxib alone in the pilot study.
